| Pair Name | Honokiol, Osimertinib | ||
| Phytochemical Name | Honokiol (PubChem CID: 72303 ) | ||
| Anticancer drug Name | Osimertinib (PubChem CID: 71496458 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Honokiol, Osimertinib | |||
| Disease Info | [ICD-11: 2C25.Z] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | MCL1 | hsa4170 |
| In Vitro Model | PC-9 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_B260 |
| PC-9-GR-high | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_S706 | |
| HCC827 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_2063 | |
| NCI-H1975/OSIR | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_WV99 | |
| In Vivo Model | The treatments included vehicle control, Osim (10 mg/kg/day, 5 days/week, og), HNK (50 mg/kg/day; ip), and their combination. | |||
| Result | Our findings warrant further study of HNK and its derivatives in overcoming Osim resistance in the clinic. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. Mol Oncol. 2020 Apr;14(4):882-895. doi: 10.1002/1878-0261.12645. | Click |
